DOW Jones drops despite broader rally, as healthcare stocks tank on Trump’s order
DOW Jones lost 178 points, dragged down by reduced profit expectations from major U.S. healthcare firms.
Stock markets are rallying thanks to the China-U.S. tariff de-escalation, but the DOW Jones is still lagging. On Tuesday, May 13, the S&P 500 was at 5,893 points, up 50 points or 0.85%, entering positive territory for the year of 2025. The tech-focused Nasdaq was trading at 21,222.80, up 354.652 points or 1.7%.
At the same time, DOW Jones was at 42,250.67 points, down 159.43 or 0.38%. This is despite the fact that positive developments in U.S.-China trade relations boosted tech stocks. For instance, Nvidia was up 5.79%, Amazon was up 1.64%, while IBM gained 1.87%.
DOW Jones Industrial Average heat map | Source: Tipranks
Healthcare stocks hammered by Trump’s new move
Still, gains from Nvidia and Amazon were outweighed by Microsoft’s loss of 0.28%, as well as significant losses from healthcare firms. For instance, Johnson & Johnson lost 3.04%, while Merck lost 3.18%, both companies involved in healthcare.
What is more, UnitedHealth lost an astonishing 16.34% after an abrupt exit by its long-time CEO, Andrew Witty. The company also suspended its annual price forecast, citing rising medical costs for the decision.
Health care stocks have been on the decline after U.S. President Donald Trump signed an executive order aimed at slashing prescription drug prices. The administration directed companies to cut drug prices to similar levels to what patients in other countries are paying. For those that don’t comply, the White House has threatened escalating, yet unspecified measures to keep them in line.
Analysts estimated that cutting drug prices in the U.S. could cut 2028 net income for the world’s pharmaceutical industry by 8%. Still, while the move would cut into the profits of healthcare firms, it might bring relief to Americans struggling with rising healthcare costs.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The Shopify Stock Rally Isn't Done: Chart of the Week -- Barrons.com
By Doug Busch Shopify is no longer a pandemic-era growth story that simply failed to slow down. It is compounding at a pace few software platforms its size still manage. In the second quarter of 2026, sales on its platform rose 32%. That was the fifth straight quarter of growth exceeding 30%. Merchants are also using more of Shopify's own tools, from payments to Shop Pay, and new channels like AI shopping agents are starting to increase demand. The simple bull case is that the stock already commands a huge share of independent online commerce, and that position should become more valuable as more buying moves through its checkout. A rule of market mechanics is that the vast majority of an individual security's gain is driven by its underlying sector. Within technology, software has staged a robust recovery, joining semiconductors to power the broader sector higher. The iShares Expanded Tech-Software Sector ETF has maintained an upward trajectory since its mid-April lows, though the advance from $74 to $112 has been choppy as bulls repeatedly stepped in to defend when necessary. Breadth across large-cap software has expanded significantly, with 24 constituents surging over 20% over the past three months. During that same three-month window, Shopify generated outstanding relative strength, advancing 36%, more than doubling the IGV's 17% gain over the same period. Expect the stock's outperformance to persist as software momentum broadens. Let's examine the daily and monthly charts to outline the technical drivers behind this thesis. Looking at the daily chart, the ratio chart against the IGV shows persistent outperformance extending back to mid-May. The stock is riding an eight-session winning streak, during which price action cleared a double-bottom-with-handle pivot at $151.39. Within this broader base, the stock recorded a bullish golden cross in late August and successfully filled its Sept. 10 price gap, tracing back to its Aug. 4 session, the day before a powerful earnings reaction sent the stock surging 17% hi
TRexBio: IPO Of 8.3M Shares Priced at $14.00 Each >TRXB
TRexBio: IPO Of 8.3M Shares Priced at $14.00 Each >TRXB
Talos Energy director Barbara J. Faulkenberry files initial beneficial ownership statement
Talos Energy director Barbara J. Faulkenberry filed an initial Form 3 statement dated Oct. 1, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Talos Energy Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-418248), on October 08, 2026, and is solely responsible for the information contained therein.
Crypto prices
More
